



Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

February 28, 2022

BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 28, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:

- **Cowen 42nd Annual Health Care Conference**
Date: Monday, March 7th at 12:50 p.m. Eastern Time
- **Barclays Global Healthcare Conference**
Date: Thursday, March 17th at 9:00 a.m. Eastern Time
- **H.C. Wainwright & Co. Gene Editing and Therapy Conference 2022**
Date: Wednesday, March 30th at 7:00 a.m. Eastern Time

Access links for presentations, panels and fireside chats will be available on the Sangamo Therapeutics website in the Investors and Media section under [Events and Presentations](#). The presentations will also be available on the Sangamo Therapeutics website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don't exist. For more information about Sangamo, visit www.sangamo.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220228005783/en/): <https://www.businesswire.com/news/home/20220228005783/en/>

Investor Relations & Media Inquiries
Aron Feingold
628.252.7494
afeingold@sangamo.com

Source: Sangamo Therapeutics, Inc.